PE20081489A1 - Derivados de espiro-piperidina - Google Patents
Derivados de espiro-piperidinaInfo
- Publication number
- PE20081489A1 PE20081489A1 PE2007001737A PE2007001737A PE20081489A1 PE 20081489 A1 PE20081489 A1 PE 20081489A1 PE 2007001737 A PE2007001737 A PE 2007001737A PE 2007001737 A PE2007001737 A PE 2007001737A PE 20081489 A1 PE20081489 A1 PE 20081489A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- alkylene
- halogen
- spiro
- spyro
- Prior art date
Links
- JUXAVSAMVBLDKO-UHFFFAOYSA-N 1-(1-azabicyclo[2.2.2]octan-3-yl)-3-[3-(1h-indol-3-yl)-1-oxo-1-spiro[1,2-dihydroindene-3,4'-piperidine]-1'-ylpropan-2-yl]urea Chemical class C1N(CC2)CCC2C1NC(=O)NC(C(=O)N1CCC2(C3=CC=CC=C3CC2)CC1)CC1=CNC2=CC=CC=C12 JUXAVSAMVBLDKO-UHFFFAOYSA-N 0.000 title abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE ESPIRO-PIPERIDINA DE FORMULA (I), EN DONDE X ES O u CH2; R1 ES H O ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO POR CN u OH; R2 ES H, ALQUILO(C1-C6), ALCOXI(C1-C6), ALQUILENO(C1-C6)NRcRd, ALQUILENO(C1-C6)-C(O)Rf, BENCILO, FENILO OPCIONALMENTE SUSTITUIDOS; R3 ES H, ALQUILO(C1-C6); R4 ES H, HALOGENO, ALQUILO(C1-C6), ENTRE OTROS; R5 ES H, HALOGENO, ENTRE OTROS; R6 ES H, ALQUILO(C1-C6), ALQUILENO(C1-C6)NRgRh, ENTRE OTROS; R7 ES H O ALQUILO(C1-C6); R8, R9, R10 Y R11 SON INDEPENDIENTEMENTE H, HALOGENO, ALQUILO(C1-C6), ENTRE OTROS. SON SELECCIONADOS: 1-[5-CLORO-1-METIL-1H-INDOL-2-IL)CARBONIL]ESPIRO[3,1-BENZOXAZINA-4,4'-PIPERIDIN]-2(1H)-ONA, {2-[(2-OXO-1,2-DIHIDRO-1'H-ESPIRO[3,1-BENZOXAZINA-4,4'-PIPERIDIN]-1'-IL)CARBONIL]-1H-INDOL-1-IL}ACETONITRILO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE LA V1a, SIENDO UTILES EN EL TRATAMIENTO DE LA ANSIEDAD, TRASTORNOS DEPRESIVOS Y OTRAS ENFERMEDADES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06125645 | 2006-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081489A1 true PE20081489A1 (es) | 2008-10-30 |
Family
ID=39201604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001737A PE20081489A1 (es) | 2006-12-07 | 2007-12-06 | Derivados de espiro-piperidina |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8022213B2 (es) |
| EP (1) | EP2099799B1 (es) |
| JP (1) | JP2010511654A (es) |
| KR (1) | KR101111022B1 (es) |
| CN (1) | CN101541797A (es) |
| AR (1) | AR064136A1 (es) |
| AT (1) | ATE469899T1 (es) |
| AU (1) | AU2007329066B2 (es) |
| BR (1) | BRPI0720246A2 (es) |
| CA (1) | CA2670671A1 (es) |
| CL (1) | CL2007003483A1 (es) |
| DE (1) | DE602007006989D1 (es) |
| ES (1) | ES2343286T3 (es) |
| IL (1) | IL198549A0 (es) |
| MX (1) | MX2009005507A (es) |
| NO (1) | NO20091766L (es) |
| PE (1) | PE20081489A1 (es) |
| RU (1) | RU2009119393A (es) |
| TW (1) | TW200843758A (es) |
| WO (1) | WO2008068159A1 (es) |
| ZA (1) | ZA200903175B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101273046B (zh) * | 2005-09-28 | 2011-05-25 | 弗·哈夫曼-拉罗切有限公司 | 作为加压素受体拮抗剂的吲哚-3-基-羰基氮杂螺环衍生物 |
| KR101372743B1 (ko) * | 2009-01-30 | 2014-03-14 | 에프. 호프만-라 로슈 아게 | Ｎｋ3 수용체 길항제로서 피페리딘 유도체 |
| US8324250B2 (en) * | 2009-03-19 | 2012-12-04 | Hoffmann-La Roche Inc. | Piperidine derivatives as NK3 receptor antagonists |
| HRP20180160T1 (hr) | 2013-12-19 | 2018-02-23 | F. Hoffmann - La Roche Ag | Spiro-oksazoloni |
| KR102765806B1 (ko) * | 2017-09-05 | 2025-02-10 | 블랙손 테라퓨틱스, 인크. | 바소프레신 수용체 길항제 및 그와 관련된 제품 및 방법 |
| WO2020048829A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 3,9-diazaspiro[5.5]undecane compounds |
| WO2020048828A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Pharma Aktiengesellschaft | 5-heteroaryl-3,9-diazaspiro[5.5]undecane compounds |
| WO2020048826A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048831A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds |
| WO2020048830A1 (en) | 2018-09-03 | 2020-03-12 | Bayer Aktiengesellschaft | 5-aryl-3,9-diazaspiro[5.5]undecan-2-one compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CO5150201A1 (es) | 1998-09-07 | 2002-04-29 | Hoffmann La Roche | Derivados de piperidina |
| CN1174979C (zh) | 2000-05-12 | 2004-11-10 | 索尔瓦药物有限公司 | 哌嗪和哌啶化合物 |
| MXPA05003948A (es) | 2002-10-17 | 2005-06-17 | Amgen Inc | Derivados de bencimidazol y su uso como ligandos de receptor vaniloide. |
| EP1701959A1 (en) * | 2003-12-22 | 2006-09-20 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
| US7351706B2 (en) * | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
-
2007
- 2007-11-27 WO PCT/EP2007/062857 patent/WO2008068159A1/en not_active Ceased
- 2007-11-27 RU RU2009119393/04A patent/RU2009119393A/ru not_active Application Discontinuation
- 2007-11-27 BR BRPI0720246-6A patent/BRPI0720246A2/pt not_active IP Right Cessation
- 2007-11-27 CN CNA2007800432751A patent/CN101541797A/zh active Pending
- 2007-11-27 JP JP2009539698A patent/JP2010511654A/ja not_active Ceased
- 2007-11-27 MX MX2009005507A patent/MX2009005507A/es active IP Right Grant
- 2007-11-27 KR KR1020097011663A patent/KR101111022B1/ko not_active Expired - Fee Related
- 2007-11-27 ES ES07847384T patent/ES2343286T3/es active Active
- 2007-11-27 AU AU2007329066A patent/AU2007329066B2/en not_active Ceased
- 2007-11-27 EP EP07847384A patent/EP2099799B1/en not_active Not-in-force
- 2007-11-27 CA CA002670671A patent/CA2670671A1/en not_active Abandoned
- 2007-11-27 DE DE602007006989T patent/DE602007006989D1/de active Active
- 2007-11-27 AT AT07847384T patent/ATE469899T1/de active
- 2007-11-30 US US11/947,836 patent/US8022213B2/en not_active Expired - Fee Related
- 2007-11-30 US US11/947,822 patent/US7432259B2/en not_active Expired - Fee Related
- 2007-12-04 CL CL200703483A patent/CL2007003483A1/es unknown
- 2007-12-04 TW TW096146110A patent/TW200843758A/zh unknown
- 2007-12-05 AR ARP070105427A patent/AR064136A1/es unknown
- 2007-12-06 PE PE2007001737A patent/PE20081489A1/es not_active Application Discontinuation
-
2009
- 2009-05-04 IL IL198549A patent/IL198549A0/en unknown
- 2009-05-05 NO NO20091766A patent/NO20091766L/no not_active Application Discontinuation
- 2009-05-07 ZA ZA200903175A patent/ZA200903175B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL198549A0 (en) | 2010-02-17 |
| TW200843758A (en) | 2008-11-16 |
| RU2009119393A (ru) | 2011-01-20 |
| AR064136A1 (es) | 2009-03-18 |
| BRPI0720246A2 (pt) | 2013-12-31 |
| ZA200903175B (en) | 2010-03-31 |
| US8022213B2 (en) | 2011-09-20 |
| MX2009005507A (es) | 2009-06-03 |
| US20080161298A1 (en) | 2008-07-03 |
| ES2343286T3 (es) | 2010-07-27 |
| AU2007329066A1 (en) | 2008-06-12 |
| EP2099799A1 (en) | 2009-09-16 |
| US20080161299A1 (en) | 2008-07-03 |
| EP2099799B1 (en) | 2010-06-02 |
| US7432259B2 (en) | 2008-10-07 |
| JP2010511654A (ja) | 2010-04-15 |
| AU2007329066B2 (en) | 2012-04-12 |
| CN101541797A (zh) | 2009-09-23 |
| CA2670671A1 (en) | 2008-06-12 |
| NO20091766L (no) | 2009-07-06 |
| WO2008068159A1 (en) | 2008-06-12 |
| ATE469899T1 (de) | 2010-06-15 |
| DE602007006989D1 (en) | 2010-07-15 |
| KR101111022B1 (ko) | 2012-03-14 |
| KR20090080112A (ko) | 2009-07-23 |
| CL2007003483A1 (es) | 2008-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081489A1 (es) | Derivados de espiro-piperidina | |
| US7872133B2 (en) | Tricyclic heterocycle compound | |
| ES2734735T3 (es) | Derivados de 4-oxo-3,4-dihidro-1,2,3,-benzotriazina como moduladores de GPR139 | |
| PE20090441A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA | |
| PE20081844A1 (es) | DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a | |
| PE20020062A1 (es) | 5-AMINO-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PIRIMIDINA COMO ANTAGONISTAS RECEPTORES DE ADENOSINA A2a | |
| PE20091315A1 (es) | Ciclopentanos de pirimidilo como inhibidores de la proteina cinasa akt | |
| PE20060150A1 (es) | Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion | |
| EP1685115A1 (en) | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | |
| RU2010135253A (ru) | Агонисты мускариновых рецепторов, композиции и способы лечения с их применением и способы их получения 177 | |
| JP2015506368A (ja) | 新規なインドリジン化合物、それらの調製方法及びそれらを含有する医薬組成物 | |
| CA2628131A1 (en) | Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods | |
| PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
| PE20090622A1 (es) | Nuevos derivados de bencimidazol sustituido | |
| PE20080182A1 (es) | Derivados pirrolo-quinoxalinona como antibacterianos | |
| PE20091353A1 (es) | Nuevos compuestos heterociclicos | |
| PE20050141A1 (es) | DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA | |
| ES2446866T3 (es) | 5-[5-[2-(3,5-Bis(trifluorometil)fenil)-2-metilpropanoilmetilamino]-4-(4-fluoro-2-metilfenil)]-2-piridinil-2-alquil-prolinamida como antagonistas del receptor nk1 | |
| PE20231215A1 (es) | Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos | |
| EP3201195A1 (en) | Spirocyclic derivatives | |
| PE20081574A1 (es) | DERIVADOS DE INDOL-2-IL-CARBONIL-PIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR DE LA V1a | |
| PE20081833A1 (es) | Derivados de espiro-piperidina | |
| PE20090829A1 (es) | Espiroindolinas como moduladores de receptores de quimioquinas | |
| AR055321A1 (es) | Compuestos de imidazopiridina uso para a fabricacion de un medicamento para el tratamiento o profilaxis de enfermedades o trastornos en los que se requiere un antagonista de una bomba de acido y composicion farmaceutica que lo comprende | |
| KR20250133677A (ko) | 치환된 디하이드로피롤로[3,4-d]피리미딘 화합물 및 의학적 병태 치료에서의 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |